PO.TB10.11 · 肿瘤生物学

DKK1与癌症相关成纤维细胞在子宫内膜癌各分子亚型中的免疫抑制作用

Immunosuppressive role of DKK1 and cancer-associated fibroblasts across molecular subtypes of endometrial cancer

海报缩略图:DKK1与癌症相关成纤维细胞在子宫内膜癌各分子亚型中的免疫抑制作用
编号 6044 展板 21 时间 4/21 02:00–05:00 区域 Section 25 主讲 Casey Cosgrove, MD
分会场 Fibroblasts as Architects of the Tumor Microenvironment
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Alessandro Canella1, Danielle Glassman1, Keith Brownewell1, Caprice Eisele2, Aharon Gideon Freud2, Casey Cosgrove1

1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, OH,2Department of Pathology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH

摘要 Abstract

中文摘要
背景。子宫内膜癌(EC)是美国最普遍且导致妇科癌症相关死亡的主要原因。与许多其他癌症不同,EC的死亡率在过去二十年间持续上升。尽管免疫治疗(尤其是免疫检查点抑制剂)近期取得进展,但大多数EC患者对现有免疫治疗的响应有限或平平。TCGA分类将EC分为四种分子亚型:POLE突变型、错配修复缺陷型(MMRd)、无特定分子谱型(NSMP)和p53异常型(p53abn)。每个亚组在肿瘤生物学、免疫细胞浸润和预后方面各不相同。深入理解这些亚型和肿瘤分级之间的免疫逃逸对于改进靶向免疫治疗至关重要。Dickkopf-1(DKK1)是经典WNT通路的一种分泌型抑制剂,已成为多种实体瘤中的关键免疫抑制调控因子。高DKK1水平与髓源性抑制细胞(MDSCs)浸润增加以及乳腺癌和结直肠癌中CD8+ T细胞和NK细胞细胞毒性受抑制相关。近期一项乳腺癌研究发现基质成纤维细胞是细胞外DKK1的主要来源,可导致NK细胞细胞毒性受抑制。 方法。我们分析了来自在俄亥俄州立大学接受手术分期的新诊断、ICI初治EC患者的跨分子亚型的新鲜及FFPE肿瘤样本。提取总RNA并采用bulk RNAseq、单细胞RNAseq(scRNAseq)、GSEA和免疫解卷积进行分析。通过免疫荧光(IF)、多重IF和DSP研究肿瘤免疫和基质微环境。 结果。高级别EC肿瘤显示与肿瘤增殖、侵袭、WNT信号、免疫抑制及基质成纤维细胞增殖相关的基因和通路显著上调。DKK1表达在高级别EC肿瘤的肿瘤微环境(TME)中显著升高,且DKK1与血管周CAF极化存在空间共定位。EC细胞中未检测到DKK1表达。scRNAseq证实DKK1仅在CAFs中上调。对TCGA-UCEC数据集的分析证实DKK1显著上调,且DKK1+CAFs、免疫抑制性髓系细胞和耗竭NK细胞之间呈正相关。 结论。我们的研究结果凸显CAF来源的DKK1是高级别及侵袭性EC中的关键免疫抑制因子,提示靶向DKK1可能增强细胞毒性免疫细胞的激活并改善免疫治疗结局。
查看英文原文 English abstract
BACKGROUND . Endometrial Cancer (EC) is the most diffuse and leading cause of gynecologic cancer-related mortality in the United States. Unlike many other cancers, EC mortality has continued to rise over the past two decades. Although recent advances in immunotherapy, particularly immune checkpoint inhibitors, most EC patients have limited or modest responses to current immunotherapies. The TCGA classification stratifies EC into four molecular subtypes: POLE-mutated, mismatch repair-deficient (MMRd), no specific molecular profile (NSMP), and p53-abnormal (p53abn). Each subgroup differs in tumor biology, immune cell infiltration, and prognosis. A deeper understanding of immune evasion across these subtypes and tumor grades is critical for improving targeted immunotherapies. Dickkopf-1 (DKK1), a secreted inhibitor of the canonical WNT pathway, has emerged as a key immunosuppressive regulator in several solid tumors. High DKK1 levels correlate with increased infiltration of myeloid-derived suppressor cells (MDSCs) and suppression of CD8+ T and NK cell cytotoxicity in breast and colorectal cancer. A recent study in breast cancer identified stromal fibroblasts as major contributors to extracellular DKK1, leading to suppression of NK cell cytotoxicity. METHODS. We analyzed fresh and FFPE tumor samples across molecular subtypes from newly diagnosed, ICI-naïve EC patients who underwent surgical staging at The Ohio State University. Total RNA was extracted and analyzed using bulk RNAseq, single-cell RNAseq (scRNAseq), GSEA, and immune deconvolution. The tumor immune and stromal microenvironment was investigated by immunofluorescence (IF), multiplex IF, and DSP. RESULTS. High-grade EC tumors showed significant upregulation of genes and pathways associated with tumor proliferation, invasion, WNT signaling, immunosuppression, and stromal fibroblasts proliferation. DKK1 expression was significantly higher in the tumor microenvironment (TME) of high-grade EC tumors, with spatial colocalization of DKK1 and perivascular CAF polarization. No DKK1 expression was detected in EC cells. scRNAseq confirmed exclusive upregulation of DKK1 in CAFs. Analysis of the TCGA-UCEC dataset confirmed significant upregulation of DKK1, and a positive correlation between DKK1+CAFs, immunosuppressive myeloid cells, and exhausted NK cells. CONCLUSIONS. Our findings highlight CAF-derived DKK1 as a key immunosuppressive factor in high-grade and aggressive EC, suggesting that targeting DKK1 may enhance cytotoxic immune cell activation and improve immunotherapeutic outcomes.
利益披露 Disclosure
A. Canella, None.. D. Glassman, None.. K. Brownewell, None.. C. Eisele, None.. A. G. Freud, None.. C. Cosgrove, None.

← 返回 AACR 2026 检索